Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing to Identify an Immunogenic Cell Death-Related 5-Gene Prognostic Signature in Hepatocellular Carcinoma

References

• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345–1362. doi:10.1016/s0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567:257–261. doi:10.1038/s41586-019-0987-8
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599–616. doi:10.1038/s41571-018-0073-4
   PubMed Web of Science ®Google Scholar
• Su GL, Altayar O, O’Shea R, et al. AGA Clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162:920–934. doi:10.1053/j.gastro.2021.12.276
   PubMed Web of Science ®Google Scholar
• Peters NA, Javed AA, He J, Wolfgang CL, Weiss MJ. Association of socioeconomics, surgical therapy, and survival of early stage hepatocellular carcinoma. J Surg Res. 2017;210:253–260. doi:10.1016/j.jss.2016.11.042
   PubMed Web of Science ®Google Scholar
• Zhang G, Li R, Deng Y, Zhao L. Conditional survival of patients with hepatocellular carcinoma: results from the surveillance, epidemiology, and end results registry. Expert Rev Gastroenterol Hepatol. 2018;12:515–523. doi:10.1080/17474124.2018.1453806
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021;22. doi:10.3390/ijms22115801
   PubMedGoogle Scholar
• Zhou Z, Hu Y, Wu Y, et al. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook. Mol Immunol. 2022;151:218–230. doi:10.1016/j.molimm.2022.09.010
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8. doi:10.1136/jitc-2019-000337
   Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482–491. doi:10.1038/onc.2009.356
   PubMed Web of Science ®Google Scholar
• Zhu M, Yang M, Zhang J, et al. Immunogenic cell death induction by ionizing radiation. Front Immunol. 2021;12:705361. doi:10.3389/fimmu.2021.705361
   PubMed Web of Science ®Google Scholar
• Ventura A, Vassall A, Robinson E, et al. Extracorporeal photochemotherapy drives monocyte-to-dendritic cell maturation to induce anticancer immunity. Cancer Res. 2018;78:4045–4058. doi:10.1158/0008-5472.Can-18-0171
   PubMed Web of Science ®Google Scholar
• Turubanova VD, Balalaeva IV, Mishchenko TA, et al. Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine. J Immunother Cancer. 2019;7:350. doi:10.1186/s40425-019-0826-3
   PubMed Web of Science ®Google Scholar
• Shekarian T, Sivado E, Jallas AC, et al. Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. Sci Transl Med. 2019:11. doi:10.1126/scitranslmed.aat5025
   Web of Science ®Google Scholar
• Tong J, Tan X, Song X, et al. CDK4/6 inhibition suppresses p73 phosphorylation and activates DR5 to potentiate chemotherapy and immune checkpoint blockade. Cancer Res. 2022;82:1340–1352. doi:10.1158/0008-5472.Can-21-3062
   PubMed Web of Science ®Google Scholar
• Wang Q, Ju X, Wang J, Fan Y, Ren M, Zhang H. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. Cancer Lett. 2018;438:17–23. doi:10.1016/j.canlet.2018.08.028
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–875. doi:10.1038/nrc3380
   PubMed Web of Science ®Google Scholar
• Maharjan R, Choi JU, Kweon S, et al. A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy. Biomaterials. 2022;281:121334. doi:10.1016/j.biomaterials.2021.121334
   PubMed Web of Science ®Google Scholar
• Kepp O, Zitvogel L, Kroemer G. Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. Oncoimmunology. 2020;9:1795995. doi:10.1080/2162402x.2020.1795995
   PubMed Web of Science ®Google Scholar
• Montes de Oca R, Alavi AS, Vitali N, et al. Belantamab Mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20:1941–1955. doi:10.1158/1535-7163.Mct-21-0035
   PubMed Web of Science ®Google Scholar
• Kostopoulos IV, Kakalis A, Birmpilis A, et al. Belantamab mafodotin induces immunogenic cell death within 24 h post-administration in newly diagnosed multiple myeloma patients. Am J Hematol. 2022. doi:10.1002/ajh.26823
   PubMed Web of Science ®Google Scholar
• Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol. 2020;43:1203–1214. doi:10.1007/s13402-020-00552-2
   Web of Science ®Google Scholar
• Zhou C, Yang ZF, Sun BY, et al. Lenvatinib induces immunogenic cell death and triggers toll-like receptor-3/4 ligands in hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:697–712. doi:10.2147/jhc.S401639
   PubMed Web of Science ®Google Scholar
• Li Y, Song Z, Han Q, et al. Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis. Mol Oncol. 2022;16:2861–2880. doi:10.1002/1878-0261.13263
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li MC, Konaté MM, et al. TPM, FPKM, or normalized counts? A comparative study of quantification measures for the analysis of RNA-seq Data from the NCI patient-derived models repository. J Transl Med. 2021;19:269. doi:10.1186/s12967-021-02936-w
   PubMed Web of Science ®Google Scholar
• Ma L, Heinrich S, Wang L, et al. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun. 2022;13:7533. doi:10.1038/s41467-022-35291-5
   PubMed Web of Science ®Google Scholar
• Mangiola S, Doyle MA, Papenfuss AT. Interfacing Seurat with the R tidy universe. Bioinformatics. 2021;37:4100–4107. doi:10.1093/bioinformatics/btab404
   PubMed Web of Science ®Google Scholar
• Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179:829–845.e820. doi:10.1016/j.cell.2019.10.003
   PubMed Web of Science ®Google Scholar
• Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184:404–421.e416. doi:10.1016/j.cell.2020.11.041
   PubMed Web of Science ®Google Scholar
• Gustavsson EK, Zhang D, Reynolds RH, Garcia-Ruiz S, Ryten M. ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2. Bioinformatics. 2022;38:3844–3846. doi:10.1093/bioinformatics/btac409
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572–1573. doi:10.1093/bioinformatics/btq170
   PubMed Web of Science ®Google Scholar
• Scire J, Huisman JS, Grosu A, et al. estimateR: an R package to estimate and monitor the effective reproductive number. BMC Bioinf. 2023;24:310. doi:10.1186/s12859-023-05428-4
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Rodrigues MC, Morais JAV, Ganassin R, et al. An overview on immunogenic cell death in cancer biology and therapy. Pharmaceutics. 2022;14. doi:10.3390/pharmaceutics14081564
   Web of Science ®Google Scholar
• Li Z, Lai X, Fu S, et al. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci. 2022;9:e2201734. doi:10.1002/advs.202201734
   Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014:3:e955691. doi:10.4161/21624011.2014.955691
   Web of Science ®Google Scholar
• Fucikova J, Spisek R, Kroemer G, Galluzzi L. Calreticulin and cancer. Cell Res. 2021;31:5–16. doi:10.1038/s41422-020-0383-9
   PubMed Web of Science ®Google Scholar
• Pol JG, Plantureux C, Pérez-Lanzón M, Kroemer G. PDIA3 as a potential bridge between immunogenic cell death and autoreactivity. Oncoimmunology. 2022;11:2130558. doi:10.1080/2162402x.2022.2130558
   PubMed Web of Science ®Google Scholar
• Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008;15:1499–1509. doi:10.1038/cdd.2008.67
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010;16:3100–3104. doi:10.1158/1078-0432.Ccr-09-2891
   PubMed Web of Science ®Google Scholar
• Garg AD, Romano E, Rufo N, Agostinis P. Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ. 2016;23:938–951. doi:10.1038/cdd.2016.5
   PubMed Web of Science ®Google Scholar
• Verzi MP, Stanfel MN, Moses KA, et al. Role of the homeodomain transcription factor Bapx1 in mouse distal stomach development. Gastroenterology. 2009;136:1701–1710. doi:10.1053/j.gastro.2009.01.009
   PubMed Web of Science ®Google Scholar
• Ouyang S, Zhu G, Ouyang L, et al. Bapx1 mediates transforming growth factor-β- induced epithelial-mesenchymal transition and promotes a malignancy phenotype of gastric cancer cells. Biochem Biophys Res Commun. 2017;486:285–292. doi:10.1016/j.bbrc.2017.03.029
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu K, Huang Y, Xu L, Li X, Zhang N. Promoter hypermethylation of CHODL contributes to carcinogenesis and indicates poor survival in patients with early-stage colorectal cancer. J Cancer. 2020;11:2874–2886. doi:10.7150/jca.38815
   PubMed Web of Science ®Google Scholar
• Masuda K, Takano A, Oshita H, et al. Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 2011;17:7712–7722. doi:10.1158/1078-0432.Ccr-11-0619
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhang N, Li W, Cao J, Zhang L, Chen Y. Expression of CHODL in hepatocellular carcinoma affects invasion and migration of liver cancer cells. Oncol Lett. 2017;13:715–721. doi:10.3892/ol.2016.5466
   PubMedGoogle Scholar
• Bassiouni W, Ali MAM, Schulz R. Multifunctional intracellular matrix metalloproteinases: implications in disease. Febs j. 2021;288:7162–7182. doi:10.1111/febs.15701
   PubMed Web of Science ®Google Scholar
• Xu L, Yang H, Yan M, Li W. Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma. Clin Exp Med. 2022. doi:10.1007/s10238-022-00897-y
   Web of Science ®Google Scholar
• Roshan-Moniri M, Hsing M, Butler MS, Cherkasov A, Rennie PS. Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers. Cancer Treat Rev. 2014;40:1137–1152. doi:10.1016/j.ctrv.2014.10.005
   PubMed Web of Science ®Google Scholar
• Liu XF, Li XY, Zheng PS, Yang WT. DAX1 promotes cervical cancer cell growth and tumorigenicity through activation of Wnt/β-catenin pathway via GSK3β. Cell Death Dis. 2018;9:339. doi:10.1038/s41419-018-0359-6
   PubMed Web of Science ®Google Scholar
• Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing’s sarcoma. Mol Cancer Res. 2006;4:851–859. doi:10.1158/1541-7786.Mcr-06-0090
   PubMed Web of Science ®Google Scholar
• Susaki Y, Inoue M, Minami M, et al. Inhibitory effect of PPARγ on NR0B1 in tumorigenesis of lung adenocarcinoma. Int J Oncol. 2012;41:1278–1284. doi:10.3892/ijo.2012.1571
   PubMed Web of Science ®Google Scholar
• Toss M, Miligy I, Gorringe K, et al. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. J Clin Pathol. 2020;73:76–82. doi:10.1136/jclinpath-2019-205939
   PubMed Web of Science ®Google Scholar
• Yang L, Zeng Q, Deng Y, Qiu Y, Yao W, Liao Y. Glycosylated cathepsin V serves as a prognostic marker in lung cancer. Front Oncol. 2022;12:876245. doi:10.3389/fonc.2022.876245
   PubMed Web of Science ®Google Scholar
• Xia Y, Ge M, Xia L, Shan G, Qian H. CTSV (cathepsin V) promotes bladder cancer progression by increasing NF-κB activity. Bioengineered. 2022;13:10180–10190. doi:10.1080/21655979.2022.2061278
   PubMed Web of Science ®Google Scholar
• Wang CH, Wang LK, Wu CC, et al. Cathepsin V mediates the tazarotene-induced gene 1-induced reduction in invasion in colorectal cancer cells. Cell Biochem Biophys. 2020;78:483–494. doi:10.1007/s12013-020-00940-3
   PubMed Web of Science ®Google Scholar